Thank you

This live web event has ended. Thank you for attending.

Description

Understanding HER2 Alterations in
Advanced Non-Squamous NSCLC

Why should you register now for this webinar?

• Learn about how personalized medicine has revolutionized the treatment of patients with advanced non-small cell lung cancer (aNSCLC) with non-squamous histology
• Explore the emerging clinical relevance of HER2 (ERBB2) mutations in aNSCLC in context with other HER2 alterations
• Discuss the best practices for identifying HER2 alterations in aNSCLC with a
  practical focus on multidisicplinary collaboration

Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenter: Fred R. Hirsch MD, PhD, FASCO
You will have the opportunity to ask questions of our distinguished presenter.


CAP TODAY does not endorse any of the products or services named within.
This program is not CME accredited and no CME credit will be provided.
This webinar is sponsored by Daiichi Sankyo, Inc. and AstraZeneca.
The speaker is receiving compensation for this presentation.
©2022 Daiichi Sankyo, Inc. and AstraZeneca. All rights reserved. PP-US-8201a-1262. Last Updated 04/22